Heat Biologics Company Profile (NASDAQ:HTBX)

Analyst Ratings

Consensus Ratings for Heat Biologics (NASDAQ:HTBX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.44 (1,578.25% upside)

Analysts' Ratings History for Heat Biologics (NASDAQ:HTBX)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Roth CapitalInitiated CoverageBuy$2.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/21/2016HC WainwrightReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Noble FinancialReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Heat Biologics (NASDAQ:HTBX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/11/2016Q1($0.56)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q4($0.64)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2015Q3($0.61)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.47)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q1($0.49)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/16/2015($0.49)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2015($0.44)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.42)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.40)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.38)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/1/2014($0.30)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heat Biologics (NASDAQ:HTBX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Heat Biologics (NASDAQ:HTBX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Heat Biologics (NASDAQ:HTBX)
DateHeadline
07/22/16 04:26 PMHeat Biologics (HTBX) Suspends Proposed Offering of Common Stock; to Explore Alternative Options
07/22/16 02:51 PMHeat Biologics Suspends Planned Public Offering -
07/22/16 07:26 AMAnalyst's Checklist Stocks: Heat Biologics, Inc. (NASDAQ:HTBX) , Quintiles Transitional Holdings Inc. (NYSE:Q) - Street Updates
07/22/16 07:26 AMNotable Analysts Recommendation to Monitor: Heat Biologics, Inc. (NASDAQ:HTBX) , Amgen Inc. (NASDAQ:AMGN) - Street Updates
07/22/16 07:26 AMHeat Biologics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
07/22/16 07:26 AMTraders Watch list: Heat Biologics Inc (NASDAQ:HTBX), Polaris Industries Inc.(NYSE:PII) - NYSE Journal (press release)
07/22/16 07:26 AMTrending Analyst Recommended Stock: Heat Biologics, Inc. (NASDAQ:HTBX) - News Oracle
07/22/16 07:26 AMWhich way Heat Biologics, Inc. (NASDAQ:HTBX) insiders are heading - Review Fortune
07/22/16 07:10 AMHeat Biologics suspends proposed common stock public offering the day after announcing it -
07/22/16 07:00 AMHeat Biologics Announces Suspension of Proposed Public Offering of Common Stock - [GlobeNewswire] - DURHAM, N.C., July 22, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that the company has suspended ...
07/21/16 03:16 PM4:16 pm Heat Biologics announces an underwritten public offering of common stock for an undisclosed amount of shares -
07/21/16 03:15 PMHeat Biologics Announces Proposed Public Offering of Common Stock - [GlobeNewswire] - DURHAM, N.C., July 21, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced today that it has commenced ...
07/21/16 03:01 PMHEAT BIOLOGICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Change in Directors or -
07/20/16 02:30 PMKeeping an Eye on Unusual Volume for Heat Biologics, Inc. (NASDAQ:HTBX) - Engelwood Daily
07/20/16 02:30 PMOverview of Analysts Suggestions: ZIOPHARM Oncology Inc (NASDAQ:ZIOP) , Heat Biologics, Inc. (NASDAQ:HTBX) - Street Updates
07/18/16 09:42 AMWere Analysts Bearish Heat Biologics Inc (NASDAQ:HTBX) This Week? - Consumer Eagle
07/15/16 07:52 AMHeat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Decreased By 5.75% - Consumer Eagle
07/14/16 04:40 PMHeat Biologics, Inc. (HTBX) Updated Price Targets - FTSE News
07/07/16 06:21 AMHeat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology - [at noodls] - ComPACTsecreting OX40L increased tumor infiltrating lymphocytes in preclinical models DURHAM, N.C., July 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), an immuno-oncology company developing ...
07/06/16 09:09 AMHeat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Decreased By 5.75% - Engelwood Daily
07/01/16 07:17 AMHeat Biologics Incorporated (NASDAQ:HTBX) Sellers Covered 5.75% of Their Shorts - Press Telegraph
07/01/16 06:02 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/27/16 08:52 AMNext Weeks Broker Price Targets For Heat Biologics, Inc. (HTBX) - Fiscal Standard
06/26/16 03:56 PMAre Analysts Bearish Heat Biologics Inc (NASDAQ:HTBX) After Last Week? - Engelwood Daily
06/22/16 04:38 PMHeat Biologics, Inc. (HTBX) Current Analyst Ratings - Fiscal Standard
06/20/16 06:49 AMCoverage initiated on Heat Biologics by ROTH Capital -
06/17/16 04:25 PMRecently Issued Stock Ratings For Heat Biologics, Inc. (HTBX) - Fiscal Standard
06/06/16 06:18 AMHeat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting - [at noodls] - Poster reviews trial design and endpoints Additional data illustrates clinical and immune response correlation DURHAM, N.C., June 06, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), an immuno-oncology ...
06/02/16 04:46 PMStrong Sell Calls Count For Heat Biologics, Inc. (NASDAQ:HTBX) At 0 - Investor Newswire - Strong Sell Calls Count For Heat Biologics, Inc. (NASDAQ:HTBX) At 0Investor NewswireThe Sell calls on Heat Biologics, Inc. (NASDAQ:HTBX) were 0. Two months earlier 1 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 0. The buy recommendations were 0 and sell calls count was 0. Analyst ...and more »
06/02/16 07:17 AMBroker Watchlist: Heat Biologics, Inc. (HTBX) - Share Trading News - Broker Watchlist: Heat Biologics, Inc. (HTBX)Share Trading News05/18/2015 – Heat Biologics, Inc. was upgraded to “hold” by analysts at Zacks. The share price of Heat Biologics, Inc. (HTBX) was down -3.90% during the last trading session, with a day high of 0.72. 699487 shares were traded on Heat Biologics, Inc.'s ...
05/31/16 08:05 AMObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ... - Is stories - Is storiesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesIn most recently trading session on 5/27/2016, Heat Biologics, Inc. (NASDAQ:HTBX) climbed +5.4961% while traded on 1.1 million shares versus it's an average volume of 661.47 thousand shares. The company recorded the last trade with the price of ...and more »
05/28/16 12:37 PMHeat Biologics, Inc. (HTBX) Updated Broker Price Targets - Share Trading News - Heat Biologics, Inc. (HTBX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Heat Biologics, Inc. (HTBX). The latest reports which are currently in issue on Friday 27th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
05/26/16 12:40 PMNotable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Heat Biologics, Inc. (NASDAQ:HTBX) - Street Updates - Notable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Heat Biologics, Inc. (NASDAQ:HTBX)Street UpdatesHeat Biologics, Inc. (NASDAQ:HTBX) moved in green zone with rise of +0.02 points or +3.45% to $0.60. The company has a market worth of $10.51M.Total 352.12 thousand shares were exchanged in last trading session as opposed to average volume of ...and more »
05/11/16 06:02 AMHeat Biologics Reports First Quarter 2016 Financial Results - [at noodls] - DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/26/16 06:06 AMHeat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co. - [at noodls] - DURHAM, N.C., April 26, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/25/16 06:54 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
04/25/16 06:15 AMHeat Biologics Appoints Dr. John Prendergast to Board of Directors - [at noodls] - DURHAM, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/09/16 02:01 PMBroker Changes For Heat Biologics, Inc. (HTBX) - Risers & Fallers - NYSE Journal (press release)Broker Changes For Heat Biologics, Inc. (HTBX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Heat Biologics, Inc. (HTBX). The latest broker reports which are currently outstanding on Friday 8th of April state 0 analysts have a rating of “strong buy”, 3 analysts ...Heat Biologics (HTBX) Announces Cost Cuts; Will Reduce Workforce by ~22%StreetInsider.comHeat Biologics, Inc. (NASDAQ:HTBX) Declined More Than 2 Percent TodayNYSE Journal (press release)Heat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Increased By 196.63%SmallCapWired.comSonoran Weekly Review -Franklin Independentall 12 news articles »
04/09/16 02:01 PMAnalysts Actions to Focus: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Heat Biologics, Inc. (NASDAQ:HTBX) - Street Updates - Analysts Actions to Focus: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Heat Biologics, Inc. (NASDAQ:HTBX)Street UpdatesIn the past trading session, Heat Biologics, Inc. (NASDAQ:HTBX) highlighted downward shift of -9.6536% or -0.0641 points to $0.5999. The company traded a volume of 1.26 million shares over average volume of 420.85 thousand shares. Trailing twelve ...and more »
04/07/16 12:44 PMDurham's Heat Bio to lay off 22% of workforce, reduce trial enrollment -
04/07/16 06:12 AMHeat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones - [at noodls] - Cost-saving measures enable Heat to achieve Phase 2 HS-410 bladder cancer data readout in 4Q:16 with its current cash on-hand DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') ...
04/07/16 06:11 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with Exit or Di -
03/09/16 06:00 AMHeat Biologics’ CSO to Participate in the 27th Annual Cancer Progress Conference by Defined Health - [GlobeNewswire] - DURHAM, N.C., March 09, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that Taylor Schreiber, M.D., ...
03/07/16 03:05 PMHeat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia - [GlobeNewswire] - DURHAM, N.C., March 07, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that positive preclinical data ...
03/04/16 06:00 AMHeat Biologics to Present at the 28th Annual ROTH Conference - [GlobeNewswire] - DURHAM, N.C., March 04, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that the company is scheduled ...
03/03/16 04:02 PMHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit -
02/26/16 08:53 AMReasons to Watch: Heat Biologics, Inc. - Heat Biologics, Inc. (NASDAQ:HTBX) caters to the Healthcare space. Its weekly performance is -24.15%. On the last day of trading company shares ended up at $1.57. Heat Biologics, Inc. (NASDAQ:HTBX) distance from 50-day simple moving average (SMA50 ...
02/26/16 08:53 AMHeat Biologics (HTBX) Ceases Enrollment in HS-410 Phase 2; Shortage No Longer Reported - Heat Biologics, Inc. (Nasdaq: HTBX) announced that the company will no longer enroll new patients in its Phase 2 monotherapy trial arm evaluating HS-410 alone for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat added the monotherapy trial ...
02/23/16 10:20 AMHeat Biologics faces a delisting from Nasdaq -
02/23/16 07:46 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa -

Social

About Heat Biologics

Heat Biologics logoHeat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patient's own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HTBX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.74
  • 50 Day Moving Average: $0.6729
  • 200 Day Moving Average: $1.1298
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $12.99M
  • Beta: 0.44
  • Current Year EPS Consensus Estimate: $-0.98 EPS
  • Next Year EPS Consensus Estimate: $-1.05 EPS
Additional Links:
Heat Biologics (NASDAQ:HTBX) Chart for Saturday, July, 23, 2016